Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | PGR | P06401 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | HTR6 | P50406 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.53 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973555 | 0.85 | POLB (1.00) | PKMPOLBPGRKMT2AMAPT | |
| SCHEMBL14093757 | 0.84 | POLB (0.73) | PKMPOLBPGRKMT2AMAPT | |
| SCHEMBL7131571 | 0.84 | POLB (0.73) | PKMPOLBPGRKMT2AMAPT | |
| SCHEMBL28121844 | 0.84 | PKM (0.72) | PKMPOLBPGRKMT2AMAPT | |
| SCHEMBL28271811 | 0.84 | HTR6 (0.79) | PKMPOLBPGRKMT2AMAPT | |
| SCHEMBL28271796 | 0.83 | HTR6 (0.83) | PKMPOLBPGRKMT2AHTR6 | |
| SCHEMBL10797719 | 0.83 | POLB (0.71) | PKMPOLBPGRKMT2AHTR6 | |
| SCHEMBL28271807 | 0.83 | HTR6 (0.71) | PKMPOLBPGRKMT2AHTR6 | |
| SCHEMBL4072331 | 0.81 | PGR (0.72) | PKMPOLBPGRKMT2AMAPT | |
| SCHEMBL18382568 | 0.81 | KEAP1 (0.76) | PKMPOLBPGRKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | PKM 2001/4885POLB 1494/4885PGR 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.